Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Dose Escalation Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045 is registered in ClinicalTrials.gov with Oncomatryx Biopharma S.L. as lead sponsor.

NCT NCT07377045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07377045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Dose Escalation Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Oncomatryx Biopharma S.L.
Phase
Phase 1
Overall status
Recruiting
Start date
October 28, 2025
Completion date
March 31, 2029
Enrollment
69 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma metastatic